Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry DiseaseBusiness Wire • 02/12/24
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety ProfileBusiness Wire • 02/05/24
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial ResultsBusiness Wire • 11/01/23
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/26/23
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and WebcastBusiness Wire • 10/25/23
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)Business Wire • 10/24/23
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitBusiness Wire • 09/20/23
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsBusiness Wire • 08/08/23
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and WebcastBusiness Wire • 08/01/23
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic EditingBusiness Wire • 07/20/23
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered CapsidsBusiness Wire • 07/17/23
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion DiseaseBusiness Wire • 06/29/23
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry DiseaseBusiness Wire • 05/22/23
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical OfficerBusiness Wire • 05/16/23
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)Benzinga • 05/11/23
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Business Wire • 05/02/23
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial ResultsBusiness Wire • 04/26/23
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and WebcastBusiness Wire • 04/19/23